Follow-up program for adults previously treated with CAR T
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You previously received treatment in a CAR T-cell gene therapy study.
- The study is for people who were enrolled in a CAR T-cell trial in the past.
- You will likely be asked to share follow-up health information and possibly have check-ups as required by the protocol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.